Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotech focused on the research and development of novel therapeutics for complement-mediated diseases. CTx is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
CTx lead investigational product (CTx001) is being evaluated as a potential gene therapy for Geographic Atrophy, a leading cause of blindness.
CTx lead investigational product (CTx001) is being evaluated as a potential gene therapy for Geographic Atrophy, a leading cause of blindness.
Location: United Kingdom, England, London
Total raised: $84.66M
Founders name: Simon J. Clark; Richard Unwin
Investors 5
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| 25.02.2022 | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
| 21.04.2023 | GIMV | gimv.com |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 2
Persons 5
| Date | First Name | Last Name | Title | Location | |||
| - | Simon | J. Clark | Co-Founder | linkedin.c... | - | s*********... | - |
| - | Harry | Kwong | Associate ... | linkedin.c... | - | h*********... | - |
| - | Rafiq | Hasan | Chief Exec... | linkedin.c... | - | r***q@comp... | - |
| - | Mustafa | Munye | - | linkedin.c... | - | m*****a@co... | - |
| - | Richard | Unwin | Co-Founder | linkedin.c... | - | r*****d@co... | - |
Mentions in press and media 16
| Date | Title | Description |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 10.11.2023 | Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy. | Munich, Germany. 9 November 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the enrolment of their first participant in the ... |
| 09.11.2023 | Complement Therapeutics Enrols First US Participant | Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy Munich, Germany – 9th November 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnol... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money. In fact, both Forbion and BioGeneration Ventures announced their largest ... |
| 05.08.2023 | Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer. | Munich, Germany. 2 August 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, has announced the appointment of Dr Parisa Zamiri as its Chief Med... |
| 11.05.2023 | Il mercato del Venture Capital ad aprile 2023 | Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle startup, delle scaleup e dei round più interessanti. Purtroppo, i dati del primo trimestre 2023 confermano i trend negativi in Europa per gli... |
| 08.05.2023 | London-based startups that raised over €10M in April 2023; 12 of them are hiring right now | London’s startup ecosystem continues to flourish, attracting investors from around the globe and fostering innovation across various industries. In the dynamic landscape of the city’s entrepreneurial scene, the month of April 2023 witnessed... |
| 27.04.2023 | Complement Therapeutics appoints Dominic Moreland as Chief Financial Officer | Complement Therapeutics appoints Dominic Moreland as Chief Financial Officer Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appoint... |
| 18.04.2023 | Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases. | Munich, Germany. 17 April 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, today announced the completion of a €72 million Series A financing... |
| 17.04.2023 | Complement Therapeutics Secures €72 Million in Series A Financing | Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases • Round led by Gimv, a Belgian based private equity and venture capital firm • Round comes just 1 year a... |
Show more